is tirzepatide fda approved Grants a New Indication for Obesity Management FDA approval for Zepbound (tirzepatide)

Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026

Food slows down that absorption of alcohol

PlexusDx encourages open communication between weight loss and obstetric providers to ensure coordinated, safe care

In:JamisonDTBremanJGMeashamARAlleyneGClaesonMEvansDBetal., editors

Primary outcome was rate of acute healthcare utilization